Skip to main content
Autobound logo
Bristol Myers Squibb10-K: Restructuring

Multiple key products including Abraxane and Sprycel have already lost exclusivity

Read at SEC EDGAR

What happened

Generics have already entered the market for former key products Abraxane and Sprycel in the U.S., EU, and Japan. This established pattern of revenue loss from patent expiry underscores the company's ongoing pressure to innovate and optimize operations.

Source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-K: Restructuring

What this signalsFilings often name leadership changes, deals and spending plans.

Period
FY2025
Fiscal year end
12/31
Filed
Feb 11, 2026

More from Bristol Myers Squibb

Company page →

More 10-K signals at other companies

The full record

From the Signal API record

Details

CIK
14272
Accession number
0000014272-26-000004
Timeframe
Current year
Filing year
2026
Why it matters
Change management needs
Signal category
Workforce

Topics and mentions

Regions named

  • U.S.
  • EU
  • Japan

Extraction

Confidence
High
Relevance
70%
Sentiment
Negative
Detected
Feb 17, 2026
signal_type
sec-10k
signal_subtype
restructuring

Use this data

Get every 10-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/3f623cc6-e6dd-4312-9b3e-2de60c2ecefd returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "3f623cc6-e6dd-4312-9b3e-2de60c2ecefd",
  "signal_type": "sec-10k",
  "signal_subtype": "restructuring",
  "detected_at": "2026-02-17T06:30:02.078+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "detail": "Generics have already entered the market for former key products Abraxane and Sprycel in the U.S., EU, and Japan. This established pattern of revenue loss from patent expiry underscores the company's ongoing pressure to innovate and optimize operations.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "Multiple key products including Abraxane and Sprycel have already lost exclusivity",
    "excerpts": "For Abraxane in the U.S., EU, and Japan, generics have entered the market.",
    "relevance": 0.7,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
    "filing_date": "2026-02-11",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Change management needs",
    "signal_category": "workforce",
    "regions_mentioned": [
      "U.S.",
      "EU",
      "Japan"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.